Efecto de la administración de un oligosacárido de la leche materna en el desarrollo de diabetes tipo 1: integridad del colon
Archivos
NO SE HA AUTORIZADO la consulta de los documentos asociados
Fecha
2022-07-28
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Jaén: Universidad de Jaén
Resumen
[ES] Los trastornos gastrointestinales, y en concreto los que afectan al colon, son una de las complicaciones más comunes en la diabetes tipo 1 (DM1). Utilizando un modelo poligénico de DM1 autoinmune, se ha estudiado el efecto de la administración temprana de un oligosacárido de la leche humana (HMO) en la integridad de la pared del colon de ratones prediabéticos y diabéticos. El análisis histológico mostró un
aumento significativo en la profundidad de las criptas en animales diabéticos tratados con HMO. Este tratamiento también aumentó significativamente el número de células caliciformes independientemente
de su situación diabética. Por tanto, el tratamiento con HMO parece favorecer la proliferación de las células caliciformes con un posible efecto protector de la barrera intestinal, y un aumento de la profundidad de las criptas del colon, generando una mayor superficie de absorción que ayudaría a la adaptación de la remodelación intestinal en la DM1.
[EN] Gastrointestinal disorders, and specifically those that affect the colon, are recognized as one of the most common complications in patients with type 1 diabetes. Using a polygenic model of autoimmune DM1, the effect of early administration of a human milk oligosaccharide (HMO) on colonic wall integrity in prediabetic and diabetic mice has been studied. Histological analysis showed significant differences between prediabetic and diabetic HMO animals, the latter presenting greater depth of the crypts. HMO treatment also significantly increased the number of goblet cells regardless of their diabetic status. In view of these results, it is concluded that the treatment with HMO seems to favor the proliferation of goblet cells with a possible protective effect and, promotes an increase in the depth of the colonic crypts, generating a greater absorption surface that would help to the adaptation of intestinal remodeling generated by DM1.
[EN] Gastrointestinal disorders, and specifically those that affect the colon, are recognized as one of the most common complications in patients with type 1 diabetes. Using a polygenic model of autoimmune DM1, the effect of early administration of a human milk oligosaccharide (HMO) on colonic wall integrity in prediabetic and diabetic mice has been studied. Histological analysis showed significant differences between prediabetic and diabetic HMO animals, the latter presenting greater depth of the crypts. HMO treatment also significantly increased the number of goblet cells regardless of their diabetic status. In view of these results, it is concluded that the treatment with HMO seems to favor the proliferation of goblet cells with a possible protective effect and, promotes an increase in the depth of the colonic crypts, generating a greater absorption surface that would help to the adaptation of intestinal remodeling generated by DM1.